Whole blood thrombin generation, platelet activation test and platelet-monocyte complex formation to predict hypercoagulability in patients with multiple myeloma

Completed

• Conditions: cancer of plasma cells; Plasma cell myeloma; 10018865

• Registration Number: NL-OMON48375
• Lead Sponsor: Synapse Research Institute

Brief Summary

Trial ended prematurely

Detailed Description

Not available

Study Timeline

• Study Completion: 2020-03-11
• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 42

Inclusion Criteria

For all participants (patients and controls):
- Subjects of both gender
- Age *18
- Written informed consent from the subject

Patients with Multiple Myeloma:
- Stable condition
- Diagnosis of Multiple Myeloma
- On active treatment with IMiD
- Patient of the Meander Medical Center

Exclusion Criteria

For all participants (patients and controls):
- Age below 18
- Known abnormalities of the coagulation system
- Pregnancy
- The use of anti-coagulant drugs (low molecular weight heparin (LMWH), vitamin
K antagonists (VKAs) and direct oral anticoagulants (DOACs))
- Active infection, bleeding or other systemic diseases
For controls (relatives: family or no-family):
- Active malignancy
- Personal history of bleeding or thrombotic events

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Thrombin generation in whole blood, platelet activation and platelet-monocyte<br /><br>complex formation in patients with MM and in controls.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not apllicable</p><br>